The company has a global presence and operates in multiple countries. They have commercialized a medication for Fabry disease and are developing an investigational therapy for Pompe disease. Additionally, Amicus has a gene therapy pipeline for lysosomal storage disorders, including Batten disease. They have received funding from various investors in multiple funding rounds. Amicus Therapeutics aims to make a difference in the lives of people with life-threatening conditions by pushing innovative ideas and advancing cutting-edge technologies.